U.S. firm Novavax says its vaccine 89% effective in British study

U.S. biotechnology firm Novavax Inc. said Thursday its experimental vaccine was about 89 percent effective in preventing the disease caused by the novel coronavirus during a late-stage clinical trial conducted in Britain.The company also said in a press release the vaccine demonstrated "significant clinical efficacy" against both the rapidly emerging variants of the virus first identified in Britain and South Africa.The phase three clinical trial in Britain, where a more contagious variant has been spreading, involved more than 15,000 participants between 18 and 84 years of age, including 2…READ FULL ARTICLE